DOI: https://doi.org/10.36347/sasjm.2026.v12i10.009

Pages: 1065-1069

Introduction: Chronic inflammatory bowel diseases (IBD) mainly include two diseases: ulcerative colitis (UC) and Crohn's disease (CD). Fecal calprotectin is the most widely studied and best performing inflammation marker in IBD to date. Methods: In this study, we included patients followed for IBD (Crohn's disease and Ulcerative colitis) under anti-TNF alpha (Infliximab/Adalimumab) alone or in association with an immunosuppressive treatment. The assessment of mucosal healing for Crohn's disease was based on the Simplified Endoscopic Score for Crohn's Disease (SESCD) and for ulcerative colitis on the endoscopic subscore of the Mayo score. Fecal calprotectin levels were evaluated according to the presence/absence of mucosal healing. Results: 43 patients were included in the study, in all our patients, statistical analysis of correlation using Spearman's test shows a very strong negative correlation between CF rate and mucosal healing (r = -0.814, p < 0.001). The ROC curve shows an area under the curve of 94%. This test can therefore be considered excellent for detecting mucosal carring at one year in IBD patients on biotherapy. Using this curve and the Youden index we could determine the best Cut-Off of fecal calprotectin which is 182 µg/g in our series. Conclusions: Fecal calprotectin levels correlate significantly with endoscopic disease activity in IBD. The test appears useful in clinical practice for assessment of endoscopic activity and remission.